Trial Profile
Phase 3, Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2016
Price :
$35
*
At a glance
- Drugs Susoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Sponsors Baxalta
- 28 Jun 2016 Status changed from not stated to not yet recruiting.
- 28 Jun 2016 New trial record